Laparotomy

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
Interrupted suturesPhase 2/31 trial
Active Trials
NCT00544583Unknown80Est. Apr 2012
Cogent Biosciences
1 program
REBUILD BioabsorbableN/A1 trial
Active Trials
NCT05041530Unknown30Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heidelberg PharmaInterrupted sutures
Cogent BiosciencesREBUILD Bioabsorbable

Clinical Trials (2)

Total enrollment: 110 patients across 2 trials

NCT00544583Heidelberg PharmaInterrupted sutures

Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy

Start: Nov 2007Est. completion: Apr 201280 patients
Phase 2/3Unknown
NCT05041530Cogent BiosciencesREBUILD Bioabsorbable

Abdominal Wall Closure After Laparotomy in Oncologic Surgery

Start: Jun 2022Est. completion: Jun 202330 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space